Evaluation of efficacy of Platelet-rich plasma injection plus oral celecoxib to treat knee osteoarthritis.

Platelet-rich plasma injection plus oral celecoxib vs saline injection plus oral celecoxib to treat knee osteoarthritis:a randomized single-blind clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301167274N6

Enrollment

Registered

2013-02-16

Start date

2012-06-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Joint Disease. Arthrosis, unspecified

Interventions

Intervention 1: Intervention Group: Single injection of Platelet-Rich Plasma (5 cc) plus administration of oral celecoxib 100 mg two times a day for 3 weeks. Intervention 2: Control group: Injection o

Treatment - Drugs

Placebo

Intervention Group: Single injection of Platelet-Rich Plasma (5 cc) plus administration of oral celecoxib 100 mg two times a day for 3 weeks

Control group: Injection of Saline plus administration of celecoxib 100 mg two times a day for 3 weeks

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 40-65 years old, patients with a history of chronic (for at least 6 months) knee pain and imaging findings of degenerative changes of the joint (Kellgren Lawrence II or III at X-ray evaluation), no intra-articular injection in the last 3 months, no history of previous knee trauma or surgery. Exclusion criteria: irregular follow-up visits, taking other NSAIDs during the trial, systemic disorders such as diabetes, rheumatoid arthritis, hematological diseases (coagulopathy), severe cardiovascular diseases, infections, pregnancy, secondary osteoarthritis, patients in therapy with anticoagulants or anti-aggregants, use of NSAIDs in the last week before blood donation and patients with Hb values lower than 11 g/dl and platelet values lower than 150,000/mm 3.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain intensity. Timepoint: Baseline assessment, 1 week and 3 month and 6 month post treatment. Method of measurement: Visual Analogue Scale.	—

Secondary

Measure	Time frame
Functional outcome and quality of life. Timepoint: Baseline assessment, 1 week and 3 month and 6 month post treatment. Method of measurement: Knee Injury and Osteoarthritis Outcome Score (KOOS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Mardani Kivi MD.

Guilan University of Medical Science

dr_mohsen_mardani@yahoo.com+98 13 1321 1470

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026